Clinical Trial Update: Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial sponsored by NHLBI is evaluating nicotinamide riboside, an NAD+ precursor, for effects on immunometabolism and immunity in systemic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Nicotinamide Riboside (nicotinamide riboside)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Systemic Lupus Erythematosus (Sle) | Phase 1, Phase 2 | Status: RECRUITING